Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
FR0012333284
Wed, 05.04.2023
ABIVAX
Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
Marc’s appointment bolsters Abivax’s position as a leader in the field of chronic inflammatory bowel diseases
Corinna zur Bonsen-Thomas steps down as acting Chair and remains a Board Member
Prof. Hartmut J. Ehrlich, M.D., retires from the CEO position
PARIS, Fr [ … ]
Wed, 05.04.2023
ABIVAX
Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
Marc’s appointment bolsters Abivax’s position as a leader in the field of chronic inflammatory bowel diseases
Corinna zur Bonsen-Thomas steps down as acting Chair and remains a Board Member
Prof. Hartmut J. Ehrlich, M.D., retires from the CEO position
PARIS, Fr [ … ]
Thu, 16.03.2023
ABIVAX
Abivax adjusts its 2023 Financial Communication Calendar
PARIS, France, March 16, 2023 – 06:30 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces an updat [ … ]
Thu, 16.03.2023
ABIVAX
Abivax adjusts its 2023 Financial Communication Calendar
PARIS, France, March 16, 2023 – 06:30 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces an updat [ … ]
Mon, 13.03.2023
ABIVAX
COMPANY STATEMENT
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
PARIS, France, March 13, 2023 – 12:00 p.m. (CET) – Abivax SA (the “Company”, Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immu [ … ]
Mon, 13.03.2023
ABIVAX
COMPANY STATEMENT
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
PARIS, France, March 13, 2023 – 12:00 p.m. (CET) – Abivax SA (the “Company”, Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immu [ … ]
Thu, 23.02.2023
ABIVAX
Abivax publishes a prospectus in the context of its capital increase
PARIS, FRANCE, February 23, 2023 – 8:00 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory disease [ … ]
Thu, 23.02.2023
ABIVAX
Abivax publishes a prospectus in the context of its capital increase
PARIS, FRANCE, February 23, 2023 – 8:00 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory disease [ … ]
Wed, 22.02.2023
ABIVAX
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
This financing was led by TCGX, with participation from existing investors Invus, Deep Track Capital, Sofinnova P [ … ]
Wed, 22.02.2023
ABIVAX
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS
Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
This financing was led by TCGX, with participation from existing investors Invus, Deep Track Capital, Sofinnova P [ … ]